BIOHEART-B Reports No Share Capital Changes, Confirms Public Float Compliance for May 2026

Bulletin Express

Jun 04

Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026.

The company’s authorised share capital remained unchanged at RMB 243.42 million, comprising 235.70 million H shares and 7.71 million unlisted foreign shares, all with a par value of RMB 1.

Issued share capital was also stable. As at 31 May 2026, BIOHEART-B had 235.70 million issued H shares and 7.71 million unlisted foreign shares; no treasury shares were outstanding, and there were no share allotments, cancellations or repurchases during the month.

Management confirmed that the H-share public float continued to meet the Main Board’s 25% minimum threshold.

The return indicated no outstanding share options, warrants, convertible securities or other agreements that could dilute equity. The document was signed by Executive Director and Joint Company Secretary Wang Yuqing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168038874"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168038874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168038874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168038874","market":"hk","top_or_hot":-1,"title":"BIOHEART-B Reports No Share Capital Changes, Confirms Public Float Compliance for May 2026","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026.</p>\n<p>The company’s authorised share capital remained unchanged at RMB 243.42 million, comprising 235.70 million H shares and 7.71 million unlisted foreign shares, all with a par value of RMB 1.</p>\n<p>Issued share capital was also stable. As at 31 May 2026, BIOHEART-B had 235.70 million issued H shares and 7.71 million unlisted foreign shares; no treasury shares were outstanding, and there were no share allotments, cancellations or repurchases during the month.</p>\n<p>Management confirmed that the H-share public float continued to meet the Main Board’s 25% minimum threshold.</p>\n<p>The return indicated no outstanding share options, warrants, convertible securities or other agreements that could dilute equity. The document was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B Reports No Share Capital Changes, Confirms Public Float Compliance for May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B Reports No Share Capital Changes, Confirms Public Float Compliance for May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026.</p>\n<p>The company’s authorised share capital remained unchanged at RMB 243.42 million, comprising 235.70 million H shares and 7.71 million unlisted foreign shares, all with a par value of RMB 1.</p>\n<p>Issued share capital was also stable. As at 31 May 2026, BIOHEART-B had 235.70 million issued H shares and 7.71 million unlisted foreign shares; no treasury shares were outstanding, and there were no share allotments, cancellations or repurchases during the month.</p>\n<p>Management confirmed that the H-share public float continued to meet the Main Board’s 25% minimum threshold.</p>\n<p>The return indicated no outstanding share options, warrants, convertible securities or other agreements that could dilute equity. The document was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1168038874","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168038874","pubTimestamp":1780555426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026. The company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"BIOHEART-B报告股本无变化，确认2026年5月公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026.\nThe company’s authorised share capital remained unchanged at RMB 243.42 million, comprising 235.70 million H shares and 7.71 million unlisted foreign shares, all with a par value of RMB 1.\nIssued share capital was also stable. As at 31 May 2026, BIOHEART-B had 235.70 million issued H shares and 7.71 million unlisted foreign shares; no treasury shares were outstanding, and there were no share allotments, cancellations or repurchases during the month.\nManagement confirmed that the H-share public float continued to meet the Main Board’s 25% minimum threshold.\nThe return indicated no outstanding share options, warrants, convertible securities or other agreements that could dilute equity. The document was signed by Executive Director and Joint Company Secretary Wang Yuqing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}